Event Content

The “Why”, “How” and “When” of AI in Pharmaceutical Innovation

Last year brought about new hope and even more hype around the idea of applying artificial intelligence (AI) for “revolutionizing” drug discovery research -- via machines being able to “learn” chemistry and biology from vast amounts of experimental data to propose potent drug candidates...

Setting the Stage – AI Investment and Applications in the Life Sciences

There continues to be strong interest within the life science and healthcare industries on innovations that can yield new actionable insights and improve operational efficiencies. With a full spectrum of validated applications spanning multiple industries, AI promises to deliver new capabilities...

Qrativ Interview: Using AI for drug discovery without spending MORE billions

In an all-new podcast, Daniel Faggella talks to Murali Aravamudan, Founder and CEO of AI-driven drug discovery startup Qrativ, a joint venture by the Mayo Clinic and biotech/data science firm nference. Murali and Daniel discuss the surge of medical information...

How the value of data is upending traditional business models in oncology

It’s 1990: ten years before the initial sequencing of the Human Genome Project was completed. Only ten years after the first clinical use of the MRI and still more than a decade before the Health Insurance Portability and Accountability Act (HIPAA) would be enacted...